Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885611 | 1.00 | TLR4 (0.37) | TLR4ESR2 | |
| SCHEMBL11035502 | 0.89 | TLR4 (0.37) | TLR4ESR2 | |
| SCHEMBL10606505 | 0.89 | TLR4 (0.37) | TLR4ESR2 | |
| SCHEMBL11035500 | 0.89 | TLR4 (0.37) | TLR4ESR2 | |
| SCHEMBL10606509 | 0.89 | TLR4 (0.37) | TLR4ESR2 | |
| SCHEMBL10408304 | 0.89 | TLR4 (0.34) | TLR4ESR2 | |
| SCHEMBL10408305 | 0.89 | TLR4 (0.34) | TLR4ESR2 | |
| SCHEMBL10930771 | 0.88 | TLR4 (0.36) | TLR4ESR2 | |
| SCHEMBL10930766 | 0.88 | TLR4 (0.36) | TLR4ESR2 | |
| SCHEMBL10896353 | 0.87 | TLR4 (0.41) | TLR4ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315727-B2 | Compound having fluorinated naphthalene structure and liquid crystal composition of the same | DIC Corporation (Tokyo) (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | DIC CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| US-8916718-B2 | Compound having 2-fluorophenyloxymethane structure | DIC CORPORATION (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20140275577-A1 | COMPOUND HAVING 2-FLUOROPHENYLOXYMETHANE STRUCTURE | DIC CORPORATION (JP) | 2014-09-18 | — | — | US | disclosed |
| EP-2123623-B1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-7846514-B2 | Liquid crystal compound, liquid crystal composition and, liquid crystal display device | CHISSO CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7846514-B2 | Liquid crystal compound, liquid crystal composition and, liquid crystal display device | CHISSO CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20100073621-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | CHISSO CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100073621-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | CHISSO CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2123623-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275577-A1 | COMPOUND HAVING 2-FLUOROPHENYLOXYMETHANE STRUCTURE | PIK3CD, TEC, PIK3C3 | TLR4 1628/4885ESR2 2052/4885 |
| US-20100073621-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT | TRPV4, TRPV5, ZKSCAN2 | TLR4 1507/4885ESR2 4341/4885 |
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | TNK1, CTNND1, FLI1 | TLR4 2576/4885ESR2 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.